Filing summary
Company: Senti Biosciences Holdings, Inc. (Nasdaq: SNTI). Filing: Form 8-K reporting an event dated October 8, 2026; signed October 13, 2026. This filing concerns the company’s annual stockholder meeting and merger-related voting, not a financial reporting period.
Business context and meeting update
The company adjourned its virtual 2026 Annual Meeting without conducting business, despite having a quorum, to allow more time to solicit votes in favor of the Merger Agreement Proposal described in its September 24, 2026 proxy statement. The meeting is scheduled to reconvene on October 15, 2026, at 8:00 a.m. Pacific time, online.
- The proposals are unchanged, and all polls remain open.
- The record date remains September 23, 2026.
- Stockholders who already voted and do not wish to change their vote need take no action.
Financial information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period results.
Outlook, risks, and other matters
The filing does not provide financial guidance or an operating outlook. It states that the 8-K may be deemed solicitation material and urges stockholders to review the proxy statement and other relevant SEC filings before voting. The company and its directors and executive officers may be participants in the proxy solicitation.
Key facts for investors to verify
- Review the September 24, 2026 proxy statement for the Merger Agreement Proposal and its terms.
- Confirm the reconvened meeting details and voting procedures in the company’s proxy materials.
- Check subsequent filings for the meeting’s outcome and any updates concerning the proposed merger.